BXTA is working towards becoming one of the leading partners to hospitals and clinics worldwide in providing LDR brachytherapy to treat prostate cancer. LDR Brachytherapy is proven to be an effective and minimally invasive prostate cancer therapy with significant quality of life benefits over alternative treatments. It is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment. It is given at a short distance: localized, precise, and high-tech. Whist brachytherapy is best known for treating prostate cancer, it is also used to treat cervical, breast, and skin cancer, and can also be used to treat tumours in many other body sites. The brachytherapy seeds supplied by BXTA have been widely used over a number of years to treat prostate cancer successfully. We understand that offering prostate cancer patients brachytherapy depends on physicians having access to high quality products delivered with expertise and reliability. The supply of the correct product prescription is time-critical in brachytherapy and BXTA have in place an efficient supply chain system which is guaranteed to deliver to the highest standards. BXTA’s dedicated and experienced UK team is led by Managing Director, Saheed Rashid. He is part of a first class team of highly knowledgeable individuals that have many years of experience in the brachytherapy sector. BXTA understands what is important to their customers and are committed to delivering consistently excellent support. Visit our website to find out more: http://www.bxt-accelyon.com